New Zealand markets close in 6 hours 53 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.6200-0.2800 (-7.18%)
At close: 04:00PM EDT
3.7700 +0.15 (+4.14%)
After hours: 05:36PM EDT

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134
https://www.nrxpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chief Scientist Officer & Chairman630.2kN/A1957
Mr. Stephen H. Willard Esq.Acting Corporate Secretary, CEO & Director500kN/A1961
Mr. Richard Clavano NaridoCFO & Treasurer255.01kN/A1979
Dr. Riccardo Panicucci Ph.D.Chief Manufacturing & Technology Officer240kN/A1961
Suzanne MessereInvestor RelationsN/AN/AN/A
Dr. Philip T. Lavin Ph.D.Chief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistN/AN/AN/A
Mr. Matthew Patrick DuffyChief Business OfficerN/AN/A1963
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate governance

NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.